Program
belvarafenib
Also written as “Belvarafenib”, “HM95573, cobimetinib” and “HM95573, cetuximab”.
Its studies are mostly in Melanoma · Neoplasm Metastasis · Neoplasms, led by 2 companies.
Drug pageBelvarafenib: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hanmi Pharmaceuticalits history only | 42 open or running | phase 2since Feb 27, 2026 | Jan 15, 2015 | Sep 2029phase 2 · NCT07449754 |
| Hoffmann-La Roche | 22 open or running | phase 2since Oct 11, 2020 | Oct 11, 2020 | Dec 31, 2026phase 1 · NCT04835805 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2017Named belvarafenibINNProposed as its International Nonproprietary Name in WHO's List 118 · before, HM95573
- Oct 11, 2020First study: phase 2 study in Solid TumorsFirst studyNCT04589845 · 920 enrolled · United States, Australia, Belgium and more
- Apr 6, 2021Phase 1 study in MelanomaNCT04835805 · 65 enrolled · United States, Australia, Canada and more
Ahead
- Dec 31, 2026Primary completion: phase 1 study in MelanomaNCT04835805
- Sep 25, 2032Primary completion: phase 2 study in Solid TumorsNCT04589845
TargetBeta
“RAF serine/threonine protein kinase inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tovorafenibrule | day-one-biopharmaceuticals-inc | phase 3 | 8 |
Studies
All 2 Hoffmann-La Roche leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04835805Melanoma · United States, Australia, Canada and more | 1 | Active, not recruiting | Dec 31, 2026 | 65 |
| NCT04589845Solid Tumors · United States, Australia, Belgium and more | 2 | Active, not recruiting | Sep 25, 2032 | 920 |
How it is read
Names in the registry
- “Belvarafenib”, 3 entries
- “HM95573, cobimetinib”, 2 entries
- “HM95573, cetuximab”, 2 entries
- “HM95573”, 2 entries
Conditions, from the studies’ own filings
- Melanoma, 2 studies
- Neoplasm Metastasis, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.